These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 15561855

  • 1. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S, Phillips L, Ludwig EA, Russo R, Gajjar DA, Bello A, Ambrose PG, Costanzo C, Grasela TH, Echols R, Grasela DM.
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [Abstract] [Full Text] [Related]

  • 2. Oral garenoxacin in the treatment of acute bacterial maxillary sinusitis: a Phase II, multicenter, noncomparative, open-label study in adult patients undergoing sinus aspiration.
    Lopez Sisniega J, Profant M, Kostrica R, Waskin H.
    Clin Ther; 2007 Aug; 29(8):1632-44. PubMed ID: 17919545
    [Abstract] [Full Text] [Related]

  • 3. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN, Fritsche TR, Sader HS, Stilwell MG.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [Abstract] [Full Text] [Related]

  • 4. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.
    Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF.
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2793-7. PubMed ID: 11557471
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of garenoxacin in the treatment of upper respiratory tract infections.
    Ito M, Maruyama Y, Murono S, Wakisaka N, Kondo S, Hatano M, Nakanishi S, Miwa T, Yoshizaki T.
    Auris Nasus Larynx; 2012 Oct; 39(5):512-8. PubMed ID: 22078851
    [Abstract] [Full Text] [Related]

  • 6. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.
    Bhavnani SM, Andes DR.
    Pharmacotherapy; 2005 May; 25(5):717-40. PubMed ID: 15899734
    [Abstract] [Full Text] [Related]

  • 7. Clinical studies of garenoxacin.
    Takagi H, Tanaka K, Tsuda H, Kobayashi H.
    Int J Antimicrob Agents; 2008 Dec; 32(6):468-74. PubMed ID: 18790608
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of garenoxacin in elderly patients with respiratory tract infections.
    Ohsaki Y, Morita K, Takeda H, Kishino S, Okumura S, Fujiuchi S.
    Int J Antimicrob Agents; 2010 Jun; 35(6):603-5. PubMed ID: 20207522
    [Abstract] [Full Text] [Related]

  • 9. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L.
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [Abstract] [Full Text] [Related]

  • 10. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN, Sader HS, Stilwell MG, Fritsche TR.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [Abstract] [Full Text] [Related]

  • 11. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
    Noreddin AM, Reese AA, Ostroski M, Hoban DJ, Zhanel GG.
    Clin Ther; 2007 Dec; 29(12):2685-9. PubMed ID: 18201584
    [Abstract] [Full Text] [Related]

  • 12. Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.
    Öbrink-Hansen K, Hardlei TF, Brock B, Jensen-Fangel S, Kragh Thomsen M, Petersen E, Kreilgaard M.
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2398-404. PubMed ID: 25666151
    [Abstract] [Full Text] [Related]

  • 13. Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation.
    Tanigawara Y, Nozawa K, Tsuda H.
    Eur J Clin Pharmacol; 2012 Jan; 68(1):39-53. PubMed ID: 21796376
    [Abstract] [Full Text] [Related]

  • 14. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B.
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [Abstract] [Full Text] [Related]

  • 15. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA, Tamimi JJ, Salem II, Ibrahim H, Sallam AA.
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [Abstract] [Full Text] [Related]

  • 16. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
    Noreddin AM, Marras TK, Sanders K, Chan CK, Hoban DJ, Zhanel GG.
    Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
    [Abstract] [Full Text] [Related]

  • 17. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
    Appelbaum PC, Gillespie SH, Burley CJ, Tillotson GS.
    Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
    [Abstract] [Full Text] [Related]

  • 18. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
    Zhang J, Xu JF, Liu YB, Xiao ZK, Huang JA, Si B, Sun SH, Xia QM, Wu XJ, Cao GY, Shi YG, Zhang YY.
    J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
    [Abstract] [Full Text] [Related]

  • 19. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
    Yoo BK, Triller DM, Yong CS, Lodise TP.
    Ann Pharmacother; 2004 Oct; 38(7-8):1226-35. PubMed ID: 15187209
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
    Yoshida K, Okimoto N, Kishimoto M, Fukano H, Hara H, Yoneyama H, Moriya O, Kawanishi M, Kimura M, Matsushima T, Niki Y.
    J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.